Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Kanion & Huawe Medicine Co.,Ltd
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03720574CT.gov Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients | — | Terminated | — | — | — |
NCT03799198CT.gov Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity | — | Completed | — | — | — |
NCT03338296CT.gov Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years | — | Terminated | — | — | — |
NCT03552107CT.gov Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic | — | Completed | — | — | — |
NCT02796144CT.gov MEtformin and Lorcaserin for WeighT Loss in Schizophrenia | — | Terminated | — | — | — |
NCT02412631CT.gov Addressing Post Cessation Weight Gain | — | Terminated | — | — | — |
NCT02398669CT.gov A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age | — | Completed | — | — | — |
NCT02388568CT.gov Lifestyle Modification and Lorcaserin for Weight Loss Maintenance | — | Completed | — | — | — |
NCT02400359CT.gov Lorcaserin in Obesity: Identification of CNS Targets Using fMRI | — | Active Not Recruiting | — | — | — |
NCT02129608CT.gov Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management | — | Completed | — | — | — |
Show 11 more trialsShow fewer
NCT02019264CT.gov A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors | — | Completed | — | — | — |
NCT02022956CT.gov Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age | — | Completed | — | — | — |
NCT01987427CT.gov A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults | — | Completed | — | — | — |
NCT00829140CT.gov To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake | — | Completed | — | — | — |
NCT00828724CT.gov Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State | — | Completed | — | — | — |
NCT00828581CT.gov Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects | — | Completed | — | — | — |
NCT00603902CT.gov BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management | — | Completed | — | — | — |
NCT00603291CT.gov BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus | — | Completed | — | — | — |
NCT00395135CT.gov BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management | — | Completed | — | — | — |
NCT00116740CT.gov Safety and Efficacy of APD356 in the Treatment of Obesity | — | Completed | — | — | — |
NCT00104507CT.gov Safety and Efficacy of APD356 in the Treatment of Obesity | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lorcaserin (this asset) | Kanion & Huawe Medicine Co.,Ltd | Approved | BB · 66 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Lorcaserin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cardiovascular Disorder | — | P4 | B · 63 |
| Schizoaffective Disorder | — | P4 | B · 60 |
| Nicotine Dependence | — | P2/3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lorcaserin in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lorcaserin-obesity-disorder-60864
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →